Abstract
Nanomedicine is one of the most promising drug delivery technologies. Treatment of anterior or posterior segment ocular diseases has always been a challenging task. The primary constraint to ophthalmic drug delivery is to deliver therapeutics at the target tissue without altering protective physiological mechanisms of the eye. In the last decade, research advancements in the field of nanotechnology have met many challenges for the treatment of ocular diseases. These nanomedicines have been employed to improve stability, solubility and ocular bioavailability, and also to reduce eye irritation caused by drug candidate or the formulation. This review article is focused on the patents issued for ophthalmic formulations particularly nanomedicines during the period of 2000-2011. The patents on nanomedicines are classified in different categories such as liposomes, polymeric nanoparticles, dendrimers, micelles and nanoemulsion. Moreover, this review article also discusses the patents in which two approaches (such as nanoparticles suspended in contact lens, nanoemulsion in situ gelling system and nanoparticles delivered via iontophoresis) are combined to achieve the best formulation for ocular treatments.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
